Background and aims: The multi-kinase inhibitor sorafenib is a first-line drug for patients with advanced hepatocellular carcinoma (HCC). Treatment options for patients whose disease has progressed on sorafenib are limited. In a recent randomized controlled trial (CELESTIAL trial), patients with advanced HCC who had failed prior systemic therapy had moderate progression-free survival and overall survival advantages when treated with the multikinase inhibitor cabozantinib. However, since this treatment is costly and is accompanied by significant adverse events in a large proportion of patients, its cost-effectiveness in these patients should be determined.
Introduction
Hepatocellular carcinoma (HCC) is an often fatal cancer with continuously increasing incidence, that predominantly arises in patients with chronic liver disease. 1 The current standard of care for patients with an early stage disease, according to the Barcelona Clinic Liver Cancer (BCLC) staging classification, include liver resection, transplantation, or radiofrequency ablation (RFA), all potentially curative modalities. 2, 3 Indeed, early detection of HCC is associated with improved survival, 4 however, only about 25% of patients are detected at an early stage of their disease. For patients whose disease is detected at an advanced stage (BCLC stage C), first-line systemic therapy with either sorafenib 5 or lenvatinib 6 is currently the standard of care for patients with Child-Pugh A cirrhosis. Recently, based on results of the RESORCE study, treatment with regorafenib was approved as a second-line therapy for patients with advanced HCC who had progressed on sorafenib treatment. 7 However, subsequent analyses have called into question the cost-effectiveness of regorafenib treatment for this group of patients. 8, 9 Cabozantinib is a multi-kinase inhibitor similar in structure to regorafenib, but different in its IC 50 for various kinase activities. It is a potent inhibitor of MET and AXL kinases that are implicated in tumor proliferation and that were reported to be involved in acquisition of resistance to antiangiogenic drugs. 10 A recent phase III trial (CELESTIAL trial), demonstrated a statistically significant benefit for cabozantinib compared to placebo, in overall survival (OS; median 10.2 versus 8.2 months) and in progression-free survival (PFS; median 5.2 months versus 1.9 months). 11, 12 The inclusion criteria for the trial were patients with Child-Pugh A cirrhosis and advanced HCC who had failed prior therapy. However, despite the demonstration of a statistically significant survival benefit, the high cost of the drug as well as its substantial side effects, mandate a thorough analysis of its costeffectiveness. We developed a Markov model to investigate the cost-effectiveness of cabozantinib for patients with Child-Pugh A liver cirrhosis and advanced HCC who had failed prior treatments.
Methods
The data from the CELESTIAL trial were obtained from the published article. 11 The IRB committee of the Rabin Medical Center provided the study with an exempt from having a formal IRB approval and the need for receiving informed consent from patients because this study is a cost-effectiveness analysis based on already published data and the data obtained is completely anonymous. We constructed a Markov model according to which the initial decision is to treat patients with cabozantinib or with best supportive care alone. Patients who initially received cabozantinib could stop treatment because of either disease progression or intolerance [grade 3-4 adverse events (AEs)]. Patients who experienced progression after cabozantinib, received best supportive care. Progression to death could occur from each health state ( Figure 1 ). The outputs of the model were life-years (LYs) and quality-adjusted LYs (QALYs), which were further used to calculate the incremental cost-effectiveness ratio (ICER). The Markov model was implemented in TreeAge Pro 2018 software and statistical analyses were performed in MATLAB.
Model survival estimates
We incorporated the PFS and OS data from the CELESTIAL study into the model. We digitized the survival curves for both the experimental arm and control arm using Matlab (Supplementary Figure 1 ). We fitted these curves to parametric survival models. The most appropriate parametric model was the Weibull model. Digitization and curve fitting can be seen in the supplemental material. We used the PFS curves to estimate the duration of treatment with cabozantinib. We used the OS curves to estimate the progression to death. We used a time horizon of 60 months.
Utility estimates
We used published quality of life data to estimate the utility of patients with metastatic HCC. 7, 9 Full details of all input variables can be seen in Table 1 . In the model, patients receiving cabozantinib were deemed to have a utility of 0.76. Patients who then had progressive disease following cabozantinib were assigned a utility of 0.68. We included grade 3-4 AEs in the model that were noted to occur in a relatively large number of patients included in the trial (roughly, >10% having a particular grade 3-4 AE). Such an approach is recommended by the Institute for Clinical and Economic Review (ICER; https:// icer-review.org/methodology/icers-methods/ icer_reference_case_july-2018/). We therefore included the following AEs: hand/foot syndrome, fatigue, diarrhea, and hypertension. We assigned disutilities to these AEs based on the published literature. 13 We estimated the duration of each AE, and multiplied this by the disutility, with the result then calculated accordingly into the longterm utility. We assumed that hand/foot syndrome would have a disutility of -0.116 lasting 14 days. We assumed that fatigue would have a disutility of -0.115 lasting 10 days. We assumed that diarrhea would have a disutility of -0.103 lasting 5 days. We assumed that hypertension would not have any disutility. 
Cost estimates
Direct medical costs were calculated in US dollars in 2018. In the base case analysis, we applied a dose of cabozantinib of 60 mg daily. This cost US$15,858 per 28-day cycle, based on drug prices taken from GoodRX on 21 October 2018 (https://www.goodrx.com/). In the United States, it is very difficult to know exactly the net price of many drugs, owing to many discounts and rebates that are often not available as public information.
We believe that GoodRX provides a close estimate of the actual amount of money that changes hands. In the CELESTIAL trial, the full dose was not received by all patients. We performed an additional analysis using the cost of 36 mg daily that was the median dose received in the trial.
Although this dose will not be a true dose used by patients, it provides a good estimate of the cost at a population level.
We estimated the cost of the treatment of the relevant AEs, also using prices from GoodRX. The relevant required treatments were based on established clinical guidelines. We estimated that the treatment of hand/foot syndrome would require 60 g of clobetasol, and 1 tube of lidocaine, at a cost of US$74. We estimated that there would be no financial cost for the treatment of fatigue. We estimated that the treatment of diarrhea would require one physician visit, 60 tablets of lomotil, and 30 tablets of loperamide, at a total cost of US$86.02. We estimated that the treatment of hypertension would require 30 tablets of amlodipine, at a cost of US$7. We performed annual discounting of all costs at a rate of 3%.
Sensitivity analysis
Owing to uncertainties of the model parameters, we performed both univariable and multivariable sensitivity analyses. The univariable sensitivity analysis allows the reader to assess how much affect a specific variable has on the overall results.
In the probabilistic sensitivity analysis, the reader can assess the level of certainty there is regarding the overall results, but without specific interrogation of a specific variable. Based on another study, 14 for each input variable we assigned a range of ±20%, together with a distribution, as seen in Table 1 . In the univariable analysis, we kept all base case values constant. We ran the model multiple times each time varying only one parameter from its upper and lower boundaries of the range. In this way we could establish which individual variables had the highest impact on the ICER.
In the probability sensitivity analysis, we ran the model 10,000 times, each time randomly selecting different input values for each variable from within their individual ranges. In this way, we were able to see how the results would cluster, despite our uncertainty regarding the input variables.
Results
As outlined in Table 2 The variables with the greatest effect on the ICER in our model were related to the parameters of the survival curves of both cabozantinib and placebo, with other parameters related to adverse events having only minor influence on the ICER. Across broad variation in the ranges for each parameter, the ICER remained >US$220,000 per QALY (Figure 2 ). In the probabilistic sensitivity analysis, the cluster of results fell between US$200,000/ QALY and US$400,000/QALY when using the median dose of 36 mg daily (Figure 3 ). Figure 4 shows the cost-effectiveness acceptability curve, demonstrating 0% likelihood that cabozantinib is cost-effective at willingness-to-pay (WTP) thresholds lower than ~US$230,000 per QALY.
Discussion
Our cost-effectiveness model suggested that the ICER for cabozantinib for treating advanced HCC was approximately US$290,000/QALY, when using the median dose of 36 mg daily. Our model-based sensitivity analyses demonstrated a high level of certainty that this therapy would not be deemed to be cost-effective at conventional willingness to pay thresholds of US$50,000-150,000 per QALY.
The current armamentarium of systemic drugs for advanced HCC is very limited. 15 Although cabozantinib has provided hope for patients with this fatal disease, unfortunately the magnitude of benefit is relatively low, and comes with a high financial cost. Healthcare systems around the world will now have to grapple with the challenging question of whether to pay for this therapy. This is a US-based study, using US-based prices, and so the results are relevant only to US-based payers. Currently, reimbursement decisions in the US are not made in connection to costeffectiveness. However, there is growing concern regarding the cost and cost-effectiveness of many healthcare interventions. 16 For example, a recent analysis found that only two thirds of public health interventions are indeed cost effective. 17 Therefore, some voices have suggested the use of cost-effectiveness modeling in the early stages of drug development 18 as well as in making reimbursement decisions, 19 in order to ensure appropriate use of scarce resources. Our current analysis adds to the literature, to provide an example of how such models can be built, to guide decision making. To the best of the authors' knowledge, it is the first US-based model of this particular drug in this group of patients.
Our findings of a lack of cost-effectiveness are comparable with the finding for regorafenib in the same disease setting. 9 There are additional novel agents that have been tested in the setting of advanced HCC, such as nivolumab and pembrolizumab, however we are unaware of published costeffectiveness analyses of these agents from a US payers' perspective. In general, however, many treatments in this disease setting add a small incremental clinical benefit, at a high cost, thus are often not considered to be cost-effective. 20 The cost-effectiveness of cabozantinib would most probably be improved if there were reliable biomarkers to select only those patients most likely to benefit from the therapy. In the CELESTIAL trial, there is some suggestion that patients who had received one prior line of therapy are more likely to benefit from cabozantinib than patients who had received two prior lines of therapy. This suggestion is based on observations from the forest plot demonstrating a hazard ratio of 0.74 for one prior line compared with a hazard ratio of 0.90 for two prior lines. However, such an observation can be considered only as hypothesis generating as opposed to practice changing as this was not a preplanned analysis.
As with all research, this model has several limitations. It was a trial-based study, using data from the CELESTIAL trial. 11 All such studies are flawed from the outset, as the trial data may not appropriately correlate to the real-world data. In particular, patients recruited into the trial may not appropriately represent real-world patients receiving this therapy. The trial was limited for patients with Child-Pugh A cirrhosis and advanced HCC who had previously failed therapy with sorafenib. Patients were also predominantly ECOG performance status less than or equal to 1.
It is reasonable to assume that in the real world, patients receiving this therapy may have a poorer performance status and poorer liver function. This may impact the survival results, as well as the duration of treatment, with an expected impact on cost. In addition, understanding the net price of drugs is difficult due to secret rebates and negotiations, thus our cost estimations may be inaccurate. The actual dose used in the real world is also uncertain. Ideally, this study would be performed with input data from real-world studies. However, this is not yet possible, as there is not yet enough drug usage, in order to have available data. The very nature of a cost-effectiveness analysis to guide reimbursement decision making, means that real-world data will usually not be available.
A couple of additional issues implicated in inherent limitations of this study need attention. First, adverse events, such as hand/foot syndrome, may sometimes be managed differently by different clinicians. Some clinicians may use urea cream, which has a comparable cost to clobetasol, and is therefore unlikely to impact the overall results, as demonstrated in the tornado presentation of the univariate sensitivity analysis. In addition, some patients will receive a dose reduction following hand/foot syndrome. Such dose reductions are accounted for in our structural sensitivity analysis of 36 mg daily instead of 60 mg daily. Second, our model is structured in a way that all patients are considered to receive full supportive care, irrespective of whether they are receiving cabozantinib or not, or whether they have indeed progressed on cabozantinib, and are receiving supportive care alone. Given that all patients receive supportive care at all times that they are alive, it is not expected that there should be any difference in costs between arms of the model, therefore they were not added. There is of course some level of uncertainty regarding this issue, which is incorporated overall in the probabilistic sensitivity analysis.
